The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats

European Journal of Pharmacology(2015)

引用 13|浏览24
暂无评分
摘要
In cardiovascular diseases, reduced responsiveness of soluble guanylate cyclase (sGC) to nitric oxide (NO) upon long-term application has led to the development of NO-independent sGC stimulators (heme-dependent) and sGC activators (heme-independent). Any direct inotropic or lusitropic effects of these compounds on isolated cardiac myocytes, however, remain to be elucidated.
更多
查看译文
关键词
Riociguat (PubChem CID: 11304743),Cinaciguat (PubChem CID: 9808022),H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (PubChem CID: 1456),Isoproterenol (PubChem CID: 3779),Verapamil (PubChem CID: 62969),8-(4-Chlorophenylthio)-guanosine3′,5′-cyclic monophosphate sodium salt (8-pCPT–cGMP) (PubChem CID: 23679064)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要